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Heart FailureElevated plasma galectin-3 is associated with
near-term rehospitalization in heart failure:
A pooled analysis of 3 clinical trials
Wouter C. Meijers, MD, a James L. Januzzi, MD, b Christopher deFilippi, MD, c Aram S. Adourian, PhD, d
Sanjiv J. Shah, MD, e Dirk J. van Veldhuisen, MD, PhD, a and Rudolf A. de Boer, MD, PhD a Groningen,
The Netherlands; Boston, and Waltham, MA; Baltimore, MD; and Chicago, ILBackground Rehospitalization is a major cause for heart failure (HF)–related morbidity and is associated with
considerable loss of quality of life and costs. The rate of unplanned rehospitalization in patients with HF is unacceptably high;
current risk stratification to identify patients at risk for rehospitalization is inadequate. We evaluated whether measurement of
galectin-3 would be helpful in identifying patients at such risk.
Methods We analyzed pooled data from patients (n = 902) enrolled in 3 cohorts (COACH, n = 592; PRIDE, n = 181;
and UMD H-23258, n = 129) originally admitted because of HF. Mean patient age was between 61.6 and 72.9 years across
the cohorts, with a wide range of left ventricular ejection fraction. Galectin-3 levels were measured during index admission.
We used fixed and random-effects models, as well as continuous and categorical reclassification statistics to assess the
association of baseline galectin-3 levels with risk of postdischarge rehospitalization at different time points and the composite
end point all-cause mortality and rehospitalization.
Results Compared with patients with galectin-3 concentrations less than 17.8 ng/mL, those with results exceeding this
value were significantly more likely to be rehospitalized for HF at 30, 60, 90, and 120 days after discharge, with odds ratios
(ORs) of 2.80 (95% CI 1.41-5.57), 2.61 (95% CI 1.46-4.65), 3.01 (95% CI 1.79-5.05), and 2.79 (95% CI 1.75-4.45),
respectively. After adjustment for age, gender, New York Heart Association class, renal function (estimated glomerular
filtration rate), left ventricular ejection fraction, and B-type natriuretic peptide, galectin-3 remained an independent predictor of
HF rehospitalization. The addition of galectin-3 to risk models significantly reclassified patient risk of postdischarge
rehospitalization and fatal event at each time point (continuous net reclassification improvement at 30 days of +42.6% [95%
CI +19.9%-65.4%], P b .001).
Conclusions Among patients hospitalized for HF, plasma galectin-3 concentration is useful for the prediction of near-
term rehospitalization. (Am Heart J 2014;167:853-860.e4.)Heart failure (HF) affects millions of patients in the
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hHF hospitalization remain high,6 with enormous economic
burden driven by these readmissions; the cost to Medicare
of HF-related rehospitalization is estimated to be approx-
imately $8.7 billion in the United States.
Readmission statistics may be considered in 3 phases,
with particularly high rehospitalization rates occurring
within the first few months after hospital discharge and
during the last 2 months before death.7 The rate of
unplanned hospital readmission has been reported to
approach 25% within 30 days of initial discharge8,9 and
30%within 60 to 90 days postdischarge.10 One-fifth of the
patients with acutely decompensated HF who present at
the emergency department experience a subsequent HF
episode that primarily involves rehospitalization.11 The
high prevalence of unplanned rehospitalizations adverse-
ly affects health care costs, resource use, and quality of
care and likely will be unsustainable.
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term readmission would allow clinicians to better
focus HF disease management efforts on high-risk
patients. Early identification of excess risk using simple
blood tests that reflects underlying HF pathophysiolo-
gy may be useful adjuncts to clinical evaluation in
clinical decision making.
Galectin-3 is a β-galactoside–binding lectin with in-
fluences in numerous physiologic and pathophysiologic
processes in HF.12 Galectin-3 has shown to be a key
mediator of cardiac remodeling13,14 and organ fibrosis,15
which are 2 pathophysiologic mechanisms involved in
HF disease progression. Although galectin-3 has been
identified as a powerful predictor of mortality,16-18 the
usefulness to predict unplanned HF rehospitalization has
been less well described.
Given the potential value of galectin-3 testing for
predicting near-term clinical outcomes, we studied
whether baseline levels of circulating galectin-3 could
identify patients with HF at higher risk for near-term
rehospitalization. To do so, we studied 3 independent
clinical cohorts, together comprising 902 patients with
HF, and assessed the value of galectin-3 for prediction
of 30-, 60-, 90-, and 120-day rehospitalization and
mortality risk.Methods
Patient populations
We analyzed the rehospitalization rates of hospitalized
patients with HF in 3 separate studies, the Coordinating
Study Evaluating Outcomes of Advising and Counseling
in Heart Failure (COACH; n = 592), the Pro-BNP
Investigation of Dyspnea in the Emergency Department
(PRIDE; n = 181), and the University of Maryland Pro-
BNP for Diagnosis and Prognosis in Patients Presenting
with Dyspnea study (University of Maryland Pro-BNP for
Diagnosis and Prognosis in Patients Presenting with
Dyspnea study [UMD] H-23258; n = 129). The details of
each study have been published elsewhere19-21; blood
samples in each of the 3 cohorts were collected at the
time of study enrollment; the other analytes (natriuretic
peptides, creatinine) that are presented and used for
statistical adjustments were taken simultaneously with
the galectin-3 measurement, at the time of enrollment in
the respective studies.
In each study, data regarding rehospitalization were
available to at least 120 days of follow-up, with
complete data available for the total 902 patients. All
blood samples in these studies were obtained during
the index hospitalization with galectin-3 measured in
these index hospitalization blood samples. All studies
were reviewed and approved by local institutional
review boards, and all patients provided written
informed consent.Biochemical measurements
Plasma galectin-3 levels were determined using a
commercially available enzyme-linked immunosorbent
assay (BG Medicine, Inc, Waltham, MA). Details are
described in the online Appendix Supplementary
material.
Outcome measurements
The primary end points were rehospitalization for HF
and the composite of rehospitalization for HF and all-
cause mortality (first to occur). Rehospitalization was
defined as an unplanned overnight stay in the hospital
due to worsening HF. In each of the studies, patients
were characterized by typical symptoms and signs of HF
according to the standard criteria. All events in each
study were adjudicated by independent clinical event
committees.
Statistical methods
Baseline characteristics are presented as means and
SDs, or medians and interquartile ranges (IQRs), as
indicated, and differences across studies were assessed
by analysis of variance modeling for continuous variables
and by χ2 test or Fisher exact test for categorical
variables. Fixed-effects Mantel-Haenszel model and the
random-effects DerSimonian-Laird model were used to
generate summary pooled odds ratios (ORs). Cox
proportional hazards regression was used to generate
estimates of hazard ratios (HRs) and 95% CIs associated
with galectin-3 as a dichotomized variable.
For discrimination and reclassification analyses, the
contribution of galectin-3, dichotomized by the cutoff
value of 17.8 ng/mL, was assessed. The base model (age,
gender, New York Heart Association [NYHA] class, left
ventricular ejection fraction [LVEF], estimated glomerular
filtration rate [eGFR], and B-type natriuretic peptide [BNP]
value [logarithmically transformed]) was compared with a
model comprising these same variables plus dichotomized
galectin-3. Reclassification was assessed using both the
continuous net reclassification improvement (NRI) metric
and NRI in which 3 categories were defined by tertiles of
predicted risk.28 Areas under receiver operating charac-
teristic curves (AUROCs) derived from the base model and
from the base model plus galectin-3 were compared using
the method of deLong et al.29 which accounts for the
correlated nature of the curves.
All statistical analyses were performed at a significance
level of .05 (complete statistical elaboration in online
Appendix Supplementary material).
The research of Dr de Boer is supported by the
Innovational Research Incentives Scheme program of the
Netherlands Organization for Scientific Research (NWO
VIDI, Grant 917.13.350). BG Medicine (Waltham, MA)
provided galectin-3 measurement services for the
Table I. Baseline characteristics
Characteristics COACH (n = 592) PRIDE (n = 181) UMD H-23258 (n = 129) P value for difference⁎
Age (y), mean (SD) 70.8 (11.2) 72.9 (13.2) 61.6 (13.4) b.001
Female, n (%) 227 (38.3) 84 (46.4) 36 (27.9) .004
Systolic blood pressure (mm Hg) 117.9 (21.0) 139.2 (29.7) 143.8 (26.3) b.001
Diastolic blood pressure (mm Hg) 68.7 (12.2) 76.6 (17.9) 84.0 (19.0) b.001
Hypertension, n (%) 256 (43.2) 113 (62.4) 101 (78.3) b.001
BMI (kg/m2), mean (SD) 27.1 (5.5) 27.9 (6.3) 31.0 (9.0) b.001
Diabetes, n (%) 176 (29.7) 72 (39.8) 58 (45.0) .001
Smoker, n (%) 101 (17.4) 23 (12.7) 40 (31.3) b.001
HF history
NYHA b.001
NYHA I/II, n (%) 275 (46.5) 25 (13.9) 37 (28.7)
NYHA III, n (%) 293 (49.5) 60 (33.3) 65 (50.4)
NYHA IV, n (%) 20 (3.8) 95 (52.8) 27 (20.9)
LVEF (%), mean (SD) 33.3 (14.2) 48.2 (18.3) 37.2 (14.8) b.001
LVEF N40, n (%) 139 (23.5) 112 (61.9) 39 (30.2) b.001
Treatment
ACEi/ARB, n (%) 486 (82.1) 67 (37.0) 62 (48.1) b.001
β-Blocker, n (%) 398 (67.2) 102 (56.4) 76 (58.9) .013
Loop diuretic, n (%) 555 (93.8) 103 (56.9) 61 (47.3) b.001
Digoxin, n (%) 190 (32.1) 42 (23.2) 22 (17.1) .001
Laboratory measurements
Galectin-3 (ng/mL), median (IQR) 20.0 (10.6) 14.9 (8.9) 19.8 (12.7) b.001
Galectin-3 N17.8 ng/mL, n (%) 357 (60.3) 66 (36.5) 79 (61.2) b.001
eGFR (mL/min per 1.73 m2), mean (SD) 53.9 (20.2) 56.4 (25.0) 57.0 (24.4) .20
BNP (pg/mL), median (IQR) 448 (199-908) 386 (174-827) 609 (318-1428) b.001
NT-proBNP (pg/mL), median (IQR) 2521 (1304-5591) 4299 (1795-9970) 4109 (1532-9577) b.001
Abbreviations: BMI, Body mass index; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; n, number of subjects.
⁎ P value for difference of at least 1 study from others.
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sible for the design and conduct of this study, all study
analyses, the drafting and editing of the manuscript, and
its final contents.
Results
Baseline characteristics of the study patients in each of
the 3 studies are presented in Table I. The mean age of
patients ranged from 61.6 to 72.9 years, and the
proportion of men ranged from 53.6% to 72.1%. Most
patients were categorized as NYHA class III and IV, but
in the COACH study, which enrolled patients predis-
charge, approximately half were assessed as NYHA class
II. Mean LVEF ranged from 33% to 48%, with a mean
(SD) value of 37% (16%) across all studies. In all studies,
BNP and N-terminal pro-BNP (NT-proBNP) levels exhib-
ited evident elevation. Online Appendix Supplementary
Table I shows the baseline characteristics as a pooled
analysis of all patients (n = 902), divided based on the
galectin-3 cutoff of 17.8 ng/mL.
Patients with HF having galectin-3 levels greater than
17.8 ng/mL were more likely to be rehospitalized for HF
within 30, 60, 90, and 120 days after index discharge in all
studies (Figure 1). The pooled ORs were 2.80 (95% CI
1.41-5.57), 2.61 (95% CI 1.46-4.65), 3.01 (95% CI 1.79-
5.05), and 2.79 (95% CI 1.75-4.45) for, respectively, 30,
60, 90, and 120 days (P b .01 for all time points) (Figure 1
and Table II). The individual ORs were comparable for allstudies; because of different number of subjects and
events in each constituent study, CIs varied among studies
(Figure 1). Analyses for the secondary end point, the
composite of all-cause mortality and HF rehospitalization,
yielded similar results, with pooled ORs of 1.64 (95% CI
0.97-2.92), 1.99 (95% CI 1.16-3.39), 1.86 (95% CI 1.18-
2.94), and 1.84 (95%CI 1.19-2.86), respectively, for 30, 60,
90, and 120 days after discharge for index hospitalization
for HF (online Appendix Supplementary Figure 1).
We further evaluated whether galectin-3 levels
obtained during the index hospitalization independently
predicted subsequent hospital readmission after consid-
eration of established risk factors for HF rehospitalization.
For this analysis, we adjusted for age, gender, NYHA class,
renal function (eGFR), LVEF, and BNP levels (Table III).
We also observed that galectin-3 remained a significant
predictor when we considered the composite end point
of HF rehospitalization and all-cause mortality (online
Appendix Supplementary Table II). Cumulative hazard
analyses for the end point of HF rehospitalization, to 120
days after hospitalization discharge, are shown in Figure 2
for each study individually, with index hospitalization
galectin-3 value dichotomized as indicated to compare
low and high baseline concentrations of galectin-3.
Online Appendix Supplementary Table III provides an
overview of the exact number of end points (HF
rehospitalization and the composite end point), by
galectin-3 category and by time.
Figure 1
Odds ratio for HF rehospitalization at different time points. Forrest plot for HF rehospitalization within 30, 60, 90, and 120 days across the 3
studies for patients with galectin-3 N17.8 ng/mL. The size of the cube is proportional to the sample size of each study; the pooled analysis is
depicted by a diamond.
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pitalization for HF and mortality when added to the
clinical risk model comprising age, gender, NYHA class,
eGFR, LVEF, and BNP, at each of the 4 postdischarge
time points considered (Table IV). The addition of
galectin-3 yielded an NRI ranging from +38.4% to +42.6%
in continuous NRI analyses, and +10.7% to +19.3% in
analysis in which tertiles of base model risk were used to
define 3 risk categories (Table IV) (P b .05 for all
analyses). Improvement in classification accuracy with
galectin-3 was seen in both low-risk and intermediate-
risk categories in categorical NRI analyses, at each time
point (online Appendix Supplementary Table IV [A-D]).
Galectin-3 measurement resulted in correctly increasingthe postdischarge risk categorization in 19% to 33% of all
patients who were initially inaccurately placed into the
lowest-risk category based solely on the clinical risk
model, but who subsequently experienced a rehospita-
lization or death within 30, 60, 90, or 120 days. Finally,
the addition of galectin-3 to the base risk model resulted
in nonsignificant increases in the AUROC at each time
point (Table IV).Discussion
The main finding of our pooled analysis is that plasma
galectin-3 levels independently predict near-term HF
rehospitalization and death and yield significantly
Table III. Cox regression model for HF rehospitalization
Study Model HR (95% CI) χ2 P
COACH Galectin-3 only (N17.8 ng/mL) 2.35 (1.63-3.39) 21.1 b.001
Multivariable adjusted⁎ 1.61 (1.04-2.50) 4.47 .034
PRIDE Galectin-3 only (N17.8 ng/mL) 1.74 (1.11-2.73) 5.8 .016
Multivariable adjusted⁎ 1.64 (0.99-2.71) 3.65 .056
UMD H-23258 Galectin-3 only (N17.8 ng/mL) 1.82 (0.89-3.90) 2.4 .087
Multivariable adjusted⁎ 3.15 (1.12-8.88) 4.72 .030
⁎Adjusted for baseline age, gender, renal function (eGFR), NYHA class, log(BNP), and LVEF.
Table II. Pooled ORs for galectin-3 N17.8 ng/mL and HF rehospitalization, separately for 30, 60, 90, and 120 days, by fixed-effects and
random-effects analysis
OR (95% CI),
fixed effects P
OR (95% CI),
random
effects
Percentage of patients rehospitalized
for HF (across all studies)
≤17.8 ng/mL N17.8 ng/mL
30 d 2.80 (1.41-5.57) .003 2.78 (1.40-5.52) 3.0 7.3
60 d 2.61 (1.46-4.65) .001 2.57 (1.44-4.59) 4.5 10.0
90 d 3.01 (1.79-5.05) b.001 3.01 (1.80-5.04) 5.5 13.6
120 d 2.79 (1.75-4.45) b.001 2.79 (1.75-4.44) 7.3 15.8
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exceeding 17.8 ng/mL consistently predicted 30-, 60-, 90-,
and 120-day rehospitalization rates in 3 separate HF
cohorts, independent of age, gender, kidney function,
LVEF, NYHA class, and plasma BNP levels. These results
suggest that assessing galectin-3 levels may be useful in
the identification of patients with HF at risk for early
rehospitalization. Awareness of higher risk for near-term
events could potentially be useful in the prevention of
unplanned hospitalizations, although the current study
did not test clinical decision making guided by galectin-3.
Currently, strong emphasis is put on reducing
unplanned rehospitalization after an acute HF admission,
the incidence of which may be as high as 25% to 30%
within the 30- to 90-day postdischarge period.8,10,11,27
Hospitals have been pursuing strategies to reduce
rehospitalization incidence because of the substantial
impact on health care resources and budgets, and
associated loss of quality of life and life span in HF. Of
note, in the United States, the federal Centers for
Medicare and Medicaid Services have recently implemen-
ted regulations that impose significant penalties on
hospitals with excessive unplanned readmission rates,
particularly within the 30-day postdischarge period.30
Although this benchmark has been strongly debated,
hospitals are seeking methods to reduce the rehospitali-
zation rate for HF.31
Because reduction of HF rehospitalization is an
increasingly urgent objective, physicians and hospitals
are seeking more accurate risk stratification tools in
patients with HF, with a goal to potentially reduce near-term HF rehospitalization. Currently, several HF risk
engines or prediction models have been developed32,33;
however, to date, there is no established model in use to
help individual physicians to classify individual patients
with HF at risk for early rehospitalization. The use of
circulating biomarkers, particularly ones relevant to
aspects of HF pathophysiology, may improve the
accuracy of risk stratification as center- and clinician-
independent markers of disease severity.
Both BNP and NT-proBNP are routinely used to confirm
the diagnosis of HF,19,34 and several studies have
reported their strong prognostic value.35-38 Data from
the Biomarkers in Acute Heart Failure (BACH) trial
showed that the predictive performance of BNP, NT-
proBNP, and MR-proADM (represented as area under the
curve values for 30-day all-cause rehospitalization) is
modest at 0.569, 0.501, and 0.510, respectively.39 Our
study shows an additional value of galectin-3 independent
of natriuretic peptides. Because changes in cardiac
structure and function usually precede symptoms, an
ideal strategy for prognosis and risk profiling in HF would
not only include markers of mechanical stretch, such as
BNP or NT-proBNP, but also markers of inflammation and
remodeling. Galectin-3 has been shown a strong predic-
tor of mortality, independent of NT-proBNP levels,16-18,40
although some studies have suggested that renal function
and/or BNP levels attenuate the prognostic power of
galectin-3.41,42 In the present study, galectin-3 was a
strong predictor of outcome, even after adjustment for
eGFR and BNP levels. Although natriuretic peptides
reflect hemodynamic loading and readily respond to
Figure 2
umulative hazard analyses for the end point of HF rehospitalization
cross the 3 studies based on galectin-3. Cumulative hazard analyses
r the end point of HF rehospitalization with the baseline galectin-3
alue dichotomized to compare low (b17.8 ng/mL) and high (N17.8
g/mL) concentrations. A, COACH: log-rank P b .001 B, PRIDE: log-
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rank P = .006. C, Maryland: log-rank P = .29.ventricular stretch, galectin-3 has been shown to be a
marker of active fibrogenesis and ventricular remodeling,
and thus less responsive to unloading.43,44 It may indeed
be argued that elevated galectin-3 may signify patients
with HF and intrinsic progressive disease that are
significantly more prone to unplanned rehospitalization.
This is in line with recent observations suggesting that
patients with rising concentrations of galectin-3 (ob-
served in approximately 25% of all patients) have an
approximately 50% increase in morality and rehospitali-
zation risks.45 Clearly, rehospitalization is, beside disease-
related factors, also influenced by patient-related factors
including compliance and access to care. Nevertheless,
although the multifactorial nature of rehospitalization
makes easy solutions unlikely, biomarkers could provide
useful information in predicting which patient is more
likely be readmitted. Currently, there are no data
suggesting that specific therapies are of additional value
when galectin-3 is elevated, so that generic recommen-
dations on clinical therapy in patients with elevated
galectin-3 cannot be given.
Strengths and limitations
In our studied cohorts, rehospitalization rates were
lower than reported in the literature, possibly because of
inclusion bias in clinical trials. Some other limitations
inherent to pooled analyses must also be acknowledged,
for example, publication bias (for instance, that other
studies may have been overlooked) and heterogeneity of
results and analyses. The present analysis is a pooled
analysis of, as far as we are informed, the 3 largest acute
HF cohorts in which galectin-3 was measured and follow-
up was available after a hospitalization for HF. An
important difference among the 3 studies was that
COACH enrolled patients 1 day prior to discharge,
whereas the other 2 studies enrolled subjects at the
time of admission. Although galectin-3 is known to be a
stable marker, galectin-3 levels in COACH patients at the
day of hospitalization may have been different. However,
galectin-3 predicted near-term rehospitalization, and we
demonstrated that increased galectin-3 levels are associ-
ated with a nearly 3-fold higher likelihood of subsequent
hospitalization. We studied the predictive value in 3
different HF cohorts at 4 time points (30, 60, 90, and 120
months) and analyzed the hospitalization rates and also as
a composite end point with all-cause mortality. Our
findings across these cohorts were consistent, supporting
the possible generalizability of our results.
Conclusion
Upon discharge for hospitalization due to HF, elevated
galectin-3 levels are associated with significantly higher
risk of near-term readmission for HF, independent of age,
gender, renal function (eGFR), NYHA class, LVEF, and
natriuretic peptide levels. Galectin-3 testing may be
Table IV. Net reclassification improvement and discrimination change metrics upon the addition of galectin-3, for HF rehospitalization and fatal
event, at 30, 60, 90, and 120 days
Time
point
NRI, continuous
(95% CI) P
NRI, categorical
(95% CI) P
Base model, AUROC
(95% CI)
Base model + galectin-3,
AUROC (95% CI) P
30 d +42.6% (+19.9%-65.4%) b.001 +13.3% (+0.3%-26.3%) .044 0.682 (0.624-0.740) 0.698 (0.644-0.749) .17
60 d +39.2% (+19.2%-59.1%) b.001 +19.3% (+6.8%-31.7%) .002 0.673 (0.619-0.727) 0.693 (0.642-0.744) .12
90 d +40.1% (+22.7%-57.6%) b.001 +10.8% (+1.2%-20.5%) .027 0.684 (0.642-0.736) 0.703 (0.657-0.749) .15
120 d +38.4% (+21.9%-54.9%) b.001 +10.7% (+2.1%-19.3%) .015 0.689 (0.642-0.735) 0.700 (0.654-0.744) .27
Base model comprises age, gender, NYHA class, LVEF, eGFR, and loge(BNP) value. Continuous NRI and categorical NRI are for base model plus galectin-3 (dichotomized variable,
defined by the cutoff value of 17.8 ng/mL). Categories for categorical NRI are defined by tertiles of predicted risk at each time point.
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Volume 167, Number 6considered, likely in combination with other risk factors,
in programs aiming to reduce hospital readmission rates
for HF.
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BG medicine galectin-3 enzyme-linked immunosorbent
assay
The assay quantitatively measures the concentration
of human galectin-3 levels, with a limit of detection of
1.13 ng/mL and no reported cross-reactivity with collagen
analytes or other members of the galectin family.
Calibration of the assay was performed according to the
assay instructions for use. Concentration values were
assigned using a standard curve22 evaluated in various HF
cohorts23,24 and the general population.25 To assign
patients to relative risk categories based on galectin-3
value, a threshold value of 17.8 ng/mL was applied, in
accordance with the US Food and Drug Administration–
cleared assay labeling for risk stratification for this galectin-
3 assay. The same assay was used in all 3 analyzed studies,
and the analytical performance and coefficient of variability
of the assay have been published in detail elsewhere.22Statistical methods
Baseline characteristics are presented as means and SDs,
or medians and IQR, as indicated, and differences across
studies were assessed by analysis of variance modeling for
continuous variables and by χ2 test or Fisher exact test for
categorical variables. To pool results across studies, the
fixed-effects Mantel-Haenszel model and the random-effects
DerSimonian-Laird model were used to generate summary
pooled ORs for each end point at the prespecified time
points of 30, 60, 90, and 120 days. Univariate models
comprising solely galectin-3, dichotomized by the cutoff
value of 17.8 ng/mL, were evaluated. In separate analyses
using Mantel-Haenszel and DerSimonian-Laird models,
summary ORs were generated that were adjusted for the
baseline covariates of age, gender, NYHA class, LVEF, eGFR
(calculated using the Modification of Diet in Renal Disease
methodology), and baseline BNP value. Prior studies have
reported a broad spectrum of predictors of adverseoutcomes in HF, and in our analyses, we adjusted for
those predictors most closely associated to HF rehospitaliza-
tion in order to keep statistical models parsimonious.26,27
Cumulative incidence functions were generated
according to baseline galectin-3 category. For each
study separately, Cox proportional hazards regression
was used to generate estimates of HRs and 95% CIs
associated with galectin-3 as a dichotomized variable and
the indicated end point. In Cox regression analyses,
Martingale residuals were inspected for satisfaction of the
linearity assumption of the Cox regression models.
For discrimination and reclassification analyses, the
contribution of galectin-3, dichotomized by the cutoff
value of 17.8 ng/mL, was assessed for the prespecified
times of 30, 60, 90, and 120 days after index discharge. In
these analyses, the base model comprising age, gender,
NYHA class, LVEF, eGFR, and BNP value (logarithmically
transformed) was compared with a model comprising
these same variables plus dichotomized galectin-3, and data
from all 3 studies were merged. Reclassification was
assessed using both the continuous NRI metric, which is
a version of NRI that does not require a priori–defined
categories, and NRI in which 3 categories were defined by
tertiles of predicted risk.28 All subjects complete on all
variables in the base model and on galectin-3, and with
complete follow-up to the specified time point, were
included in reclassification calculations. Areas under
receiver operating characteristic curves derived from the
base model and from the base model plus galectin-3 were
compared using the method of deLong et al,29 which
accounts for the correlated nature of the curves.
All statistical analyses were performed at a significance
level of .05. Analyses were performed with SAS software,
version 9.1 (SAS Institute, Inc, Cary, NC), or R software,
version 3.1 (R Foundation for Statistical Computing,
Vienna, Austria). Reclassification calculations were per-
formed using the R package “PredictABEL,” version 1.2-1
(Erasmus Medical Center, Rotterdam, the Netherlands).
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Odds ratio for HF rehospitalization or death at different time points. Forest plot for HF rehospitalization or all-cause mortality within 30, 60, 90, and
120 days across the 3 studies for patients with galectin-3 N 17.8 ng/mL. The size of the cube is proportional to the sample size of each study; the
pooled analysis is depicted by a diamond.
Supplementary Table I. Baseline characteristics by galectin-3 category
Characteristic Galectin-3 ≤ 17.8 ng/mL (n = 400) Galectin-3 N 17.8 ng/mL (n = 502) P
Age (y), mean (SD) 67.8 (12.7) 71.8 (11.8) b.001
Female, n (%) 133 (33.3) 214 (42.6) .004
Systolic blood pressure (mm Hg) 126.4 (25.6) 125.5 (26.7) .61
Diastolic blood pressure (mm Hg) 73.0 (15.6) 72.0 (15.7) .36
Hypertension, n (%) 194 (48.5) 276 (55.0) .11
BMI (kg/m2), mean (SD) 28.1 (6.5) 27.7 (6.3) .39
Diabetes, n (%) 106 (26.5) 200 (39.8) b.001
Smoker, n (%) 74 (18.5) 90 (17.9) .40
HF history
NYHA .011
NYHA I/II, n (%) 169 (42.5) 168 (33.7)
NYHA III, n (%) 164 (41.2) 254 (50.9)
NYHA IV, n (%) 65 (16.3) 77 (15.4)
LVEF, mean (SD) 38.5 (17.2) 35.5 (15.6) .010
LVEF N40, n (%) 149 (37.3) 141 (28.1) .003
Treatment
ACEi/ARB, n (%) 263 (65.8) 352 (70.1) .36
β-Blocker, n (%) 256 (64.0) 320 (63.7) .60
Loop diuretic, n (%) 292 (73.0) 427 (85.1) .002
Digoxin, n (%) 107 (26.8) 147 (29.3) .54
Laboratory measurements
eGFR, mL/min per 1.73 m2, mean (SD) 65.5 (19.9) 46.4 (19.6) b.001
BNP (pg/mL), median (IQR) 389 (174-771) 511 (243-1250) b.001
NT-proBNP (pg/mL), median (IQR) 2238 (1164-4706) 3727 (1701-9803) b.001
Galectin-3 (ng/mL), median (IQR) 13.7 (4.6) 24.5 (10.2) b.001
Abbreviations: BMI, Body mass index; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.
Supplementary Table II. Cox regression model for the composite end point (HF rehospitalization and all-cause mortality)
Study Model HR (95% CI) χ2 P
COACH Galectin-3 only (N17.8 ng/mL) 2.18 (1.65-2.89) 29.5 b.001
Multivariable adjusted⁎ 1.46 (1.02-2.08) 4.33 .037
PRIDE Galectin-3 only (N17.8 ng/mL) 1.48 (1.06-2.07) 5.1 .023
Multivariable adjusted⁎ 1.41 (0.97-2.06) 3.09 .077
UMD H-23258 Galectin-3 only (N17.8 ng/mL) 1.85 (1.01-3.38) 3.9 .049
Multivariable adjusted⁎ 2.41 (1.10-5.28) 4.82 .031
⁎Adjusted for baseline age, gender, renal function (eGFR), NYHA class, log(BNP), and LVEF.
Supplementary Table III. Counts of HF rehospitalization and composite end point (HF rehospitalization and all-cause mortality) across all
studies, by galectin-3 category and by time
Galectin-3 ≤ 17.8 ng/mL Galectin-3 N 17.8 ng/mL
30 d HF rehospitalization, n (%) 11 (2.8) 39 (7.8)
Composite end point, n (%) 20 (5.0) 63 (12.6)
60 d HF rehospitalization, n (%) 16 (4.0) 53 (10.6)
Composite end point, n (%) 31 (7.8) 87 (17.3)
90 d HF rehospitalization, n (%) 21 (5.3) 72 (14.3)
Composite end point, n (%) 42 (10.5) 117 (23.3)
120 d HF rehospitalization, n (%) 28 (7.0) 83 (16.5)
Composite end point, n (%) 53 (13.3) 136 (27.1)
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Supplementary Table IV. (A-D) Reclassification tables indicating counts of patients in each risk category, by time point and by patient fate,
based on the addition of galectin-3 to the base risk model without galectin-3
Model without galectin-3 Model with galectin-3
A. T = 30 d
Patients with events b5.9% 5.9%-9.4% N9.4% % Reclassified
b5.9% 6 2 0 25%
5.9%-9.4% 2 10 10 55%
N9.4% 0 4 32 11%
Patients without events
b5.9% 221 37 0 14%
5.9%-9.4% 72 109 45 52%
N9.4% 0 40 184 18%
B. T = 60 d
Patients with events b8.5% 8.5-13.3% N13.3% % Reclassified
b8.5% 8 4 0 33%
8.5%-13.3% 5 12 19 67%
N13.3% 0 5 40 11%
Patients without events
b8.5% 208 36 0 15%
8.5%-13.3% 75 97 49 56%
N13.3% 0 46 170 21%
C. T = 90 d
Patients with events b11.8% 11.8-19.0% N19.0% % Reclassified
b11.8% 13 3 0 19%
11.8%-19.0% 7 23 17 51%
N19.0% 0 7 60 10%
Patients without events
b11.8% 206 35 0 15%
11.8%-19.0% 64 111 33 47%
N19.0% 0 44 150 23%
D. T = 120 d
Patients with events b12.1% 12.1-22.0% N22.0% % Reclassified
b12.1% 6 3 0 33%
12.1%-22.0% 4 33 21 43%
N22.0% 0 10 78 11%
Patients without events
b12.1% 87 15 0 15%
12.1%-22.0% 50 233 44 29%
N22.0% 0 35 154 19%
At each time point, patients who are complete on all variables included in the base model and on galectin-3, and with complete follow-up to the specified time point, are evaluable in
reclassification calculations. The base risk model comprises age, gender, NYHA class, LVEF, eGFR, and BNP value.
